Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
4 minute read

AstraZeneca Announced Datopotamab Deruxtecan-based Combinations Show Promising Clinical Activity in Patients With Advanced Non-small Cell Lung Cancer

By Charles Gross
Today, 5:24 PM
Initial results from the TROPION-Lung02 Phase Ib trial showed that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable safety profile in patients with previously untreated or pretreated, advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.

AZN

Read More
1 minute read

AstraZeneca Announced Calquence Tablet Formulation Approved in the US Across Current Indications

By Charles Gross
Today, 5:24 PM
AstraZeneca's new tablet formulation of Calquence (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and for patients with relapsed or refractory mantle cell lymphoma (MCL), which is approved under accelerated approval based on overall response rate.

AZN